Using artificial intelligence to diagnose 'glue ear' in children

Submission date	Recruitment status	[X] Prospectively registered
24/08/2021	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
20/09/2021	Completed	Results
Last Edited	Condition category	Individual participant data
20/09/2021	Ear, Nose and Throat	Record updated in last year

Plain English summary of protocol

Background and study aims

Otitis media with effusion (OME) (also known as 'glue ear') is one of the most common causes of childhood hearing impairment and disability. It is estimated that more than 80% of children will have otitis media before the age of 10 years. This places a significant cost burden on the NHS with about 200,000 children with OME seen annually in primary care. Delayed diagnosis and poorly managed cases can result in severe and persistent OME with surgical treatment becoming the only management option, leading to long waiting times and excessively high costs for the NHS. Recent research into AI has made great progress in demonstrating its potential for the accurate diagnosis of OME. This novel research proves the capability of AI tools to diagnose OME automatically with an accuracy of 82%. The aim of this study is to achieve the best accuracy and reliability of these AI tools.

Who can participate?

Children under 12 years old who have been attending the clinic because parents/guardians are concerned about their hearing, or for a follow-up appointment after an acute case of 'glue ear'.

What does this study involve?

The study involves a simple, fast, objective, and non-invasive middle ear measurement using a commercialised device called Wideband Absorbance Immittance (WAI) by Interacoustics after the patient has completed their routine hearing tests. Basically, a small probe will be placed in the patient's ear canal, send some quiet clicks into their ear, and record the responses from the ear canal. The WAI test is performed by a clinical researcher and this procedure will be very quick (less than 1 minute per side).

What are the possible benefits and risks of participating?

The device should lead to significant and direct impacts on clinical assessment and diagnostic concepts for childhood OME in professional communities, and the NICE guidelines for childhood OME treatment. The benefits derived from its wider use as a diagnostic tool for accurate diagnosis of OME are summarised as follows. From the child development perspective, children with OME will benefit directly from prompt and accurate diagnosis and the application of appropriate management strategies tailored to support their ongoing development in areas such as speech and language development, education and future health. In this way, the

potential risks on the child's social and future development that are associated with this condition will be removed. From the parents' perspective, early and accurate diagnosis will help minimise parental concerns regarding their child's behaviour, performance at school, or language development, particularly where GPs primarily consult for the management of earspecific symptoms only and do not start interventions immediately. The accurate, timely, efficient, equitable and patient-centred delivery of the enhanced quality healthcare will directly increase parental satisfaction. Because the WAI test is a simple, fast, objective, and non-invasive middle ear measurement using a commercialised device by Interacoustics after the participants have completed their routine hearing assessment, there should not be any significant risks in completing this study.

Where is this study run from? Noah's Ark Children's Hospital for Wales and the Child Health Centre in St David's Hospital, Cardiff (UK)

When is the study starting and how long is it run for? November 2020 to September 2022

Who is funding this study? National Institute for Health Research (NIHR) (UK)

Who is the main contact? Dr Fei Zhao fzhao@cardiffmet.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Fei Zhao

ORCID ID

https://orcid.org/0000-0002-0936-4447

Contact details

200 Western Avenue Cardiff United Kingdom CF5 2YB +44 (0)2920417290 fzhao@cardiffmet.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 304420

Study information

Scientific Title

Development of an artificial intelligence system for the automated diagnosis of otitis media with effusion in children

Acronym

DAISYDOME

Study objectives

The newly developed Artificial Intelligence (AI) techniques provide an accurate and reliable automated diagnosis of childhood otitis media with effusion (OME).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval pending, South East Wales Research Ethics Committee

Study design

Two-arm randomized parallel study

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Otitis media

Interventions

The study involves a simple, fast, objective, and non-invasive middle ear measurement using a commercialised device called Wideband Absorbance Immittance (WAI) by Interacoustics after the patient completed their routine hearing assessments. Basically, a small probe will be placed in the patient's ear canal, sending some quiet clicks into their ear, and recording the responses from the ear canal. The WAI test is performed by a clinical researcher and this procedure is very quick (less than 1 minute per test).

The participants will be randomly assigned to two groups that differ according to whether clinicians take the output provided by the AI-WAI support tool into account when making decisions or not:

Group A (diagnostic decision without AI-WAI support tool): clinicians will make their diagnostic decision and subsequent management based on traditional assessments, according to The National Institute for Clinical Excellence (NICE) guideline for otitis media with effusion in under 12s: surgery (2008). They will not be informed of the test results given by the AI-WAI system.

Group B (diagnostic decision with consideration of AI-WAI output): the clinician will be informed of the outcomes provided by AI-WAI support tool. As a result, they will make the diagnostic decision by considering the AI-WAI support tool.

Intervention Type

Device

Phase

Not Applicable

Primary outcome(s)

The diagnostic accuracy of the novel AI diagnostic tool compared with routine clinical practice measured at a single timepoint

Key secondary outcome(s))

Energy absorbance of the middle ear measured using the wideband absorbance immittance (WAI) device in different age groups and under various severity conditions in ears with OME at a single timepoint

Completion date

30/09/2022

Eligibility

Key inclusion criteria

Children under 12 years old attending the clinic due to parental concerns regarding hearing loss or for follow-up appointments after acute otitis media

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Upper age limit

12 years

Sex

All

Key exclusion criteria

Children with ventilation tubes in situ

Date of first enrolment

03/01/2022

Date of final enrolment

30/09/2022

Locations

Countries of recruitment

United Kingdom

Wales

Study participating centre Noah's Ark Children's Hospital for Wales, University Hospital of Wales

Heath Park Cardiff United Kingdom CF14 4XW

Study participating centre

St David's Hospital

Child Health Centre Cowbridge Road East Canton Cardiff United Kingdom CF11 9XB

Sponsor information

Organisation

Cardiff Metropolitan University

ROR

https://ror.org/00bqvf857

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

According to the data storage plan, the collected data will be stored securely on the university's ONEDrive account with password protection, in accordance with the Data Protection Act (1998), the General Data Protection Regulation and Cardiff Metropolitan University's data storage procedures. Access to them will be restricted to the internal research team. The data will be destroyed 5 years after the completion of the project. To protect participant's privacy, no names of participants will be used throughout this research project. The participants' data will be anonymised by the use of a participant reference code on the middle ear measurement data. In regards to data sharing, according to the data policy for publications in professional journals, the data would be made available upon request.

IPD sharing plan summary

Available on request

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 No Yes